AAAAAA

   
Results: 1-17 |
Results: 17
Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer
Authors: Gillette-Cloven, N Burger, RA Monk, BJ McMeekin, DS Vasilev, S DiSaia, PJ Kohler, MF
Citation: N. Gillette-cloven et al., Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer, J AM COLL S, 193(6), 2001, pp. 626-632
Reimbursement for surgical procedures in gynecologic oncology
Authors: Monk, BJ Burger, RA
Citation: Bj. Monk et Ra. Burger, Reimbursement for surgical procedures in gynecologic oncology, CURR OPIN O, 13(5), 2001, pp. 390-393
Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix
Authors: McHale, MT Le, TD Burger, RA Gu, M Rutgers, JL Monk, BJ
Citation: Mt. Mchale et al., Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix, OBSTET GYN, 98(5), 2001, pp. 726-731
Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women
Authors: Chan, KJ Lin, YG Monk, BJ Tewari, K Bloss, JD Berman, ML
Citation: Kj. Chan et al., Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women, OBSTET GYN, 97(5), 2001, pp. 707-711
Intent-to-treat analysis of stage Ib and IIa cervical cancer in the UnitedStates: Radiotherapy or surgery 1988-1995
Authors: Brewster, WR Monk, BJ Ziogas, A Anton-Culver, H Yamada, SD Berman, ML
Citation: Wr. Brewster et al., Intent-to-treat analysis of stage Ib and IIa cervical cancer in the UnitedStates: Radiotherapy or surgery 1988-1995, OBSTET GYN, 97(2), 2001, pp. 248-254
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer
Authors: Welsh, JB Zarrinkar, PP Sapinoso, LM Kern, SG Behling, CA Monk, BJ Lockhart, DJ Burger, RA Hampton, GM
Citation: Jb. Welsh et al., Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer, P NAS US, 98(3), 2001, pp. 1176-1181
Primary invasive carcinoma of the vagina - Treatment with interstitial brachytherapy
Authors: Tewari, KS Cappuccini, F Puthawala, AA Kuo, JV Burger, RA Monk, BJ Manetta, A Berman, ML Disaia, PJ Syed, AMN
Citation: Ks. Tewari et al., Primary invasive carcinoma of the vagina - Treatment with interstitial brachytherapy, CANCER, 91(4), 2001, pp. 758-770
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix
Authors: Peters, WA Liu, PY Barrett, RJ Stock, RJ Monk, BJ Berek, JS Souhami, L Grigsby, P Gordon, W Alberts, DS
Citation: Wa. Peters et al., Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix, J CL ONCOL, 18(8), 2000, pp. 1606-1613
Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model
Authors: Tewari, KS Taylor, JA Liao, SY DiSaia, PJ Burger, RA Monk, BJ Hughes, CCW Villarreal, LP
Citation: Ks. Tewari et al., Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model, GYNECOL ONC, 77(1), 2000, pp. 137-148
Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus
Authors: Yamada, SD Burger, RA Brewster, WR Anton, D Kohler, MF Monk, BJ
Citation: Sd. Yamada et al., Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus, CANCER, 88(12), 2000, pp. 2782-2786
Human papillomavirus presence and survival
Authors: Monk, BJ Burger, RA
Citation: Bj. Monk et Ra. Burger, Human papillomavirus presence and survival, INT J GYN C, 9(2), 1999, pp. 173-173
Does human papillomavirus have a role in cancers of the uterine corpus?
Authors: Brewster, WR Monk, BJ Burger, RA Bergen, S Wilczynski, SP
Citation: Wr. Brewster et al., Does human papillomavirus have a role in cancers of the uterine corpus?, GYNECOL ONC, 75(1), 1999, pp. 51-54
Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer
Authors: Burger, RA DiSaia, PJ Roberts, JA O'Rourke, M Gershenson, DM Homesley, HD Lichtman, SM Barnes, W Moore, DH Monk, BJ
Citation: Ra. Burger et al., Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer, GYNECOL ONC, 72(2), 1999, pp. 148-153
Protein kinase C isoform expression and activity alter paclitaxel resistance in vitro
Authors: Chen, LG Burger, RA Zaunbrecher, GM Chen, HX Lincoln, AJ Mallarino, MC Monk, BJ Khan, SA
Citation: Lg. Chen et al., Protein kinase C isoform expression and activity alter paclitaxel resistance in vitro, GYNECOL ONC, 72(2), 1999, pp. 171-179
Interstitial brachytherapy in the treatment of advanced and recurrent vulvar cancer
Authors: Tewari, K Cappuccini, F Syed, AMN Puthawala, A DiSaia, PJ Berman, ML Manetta, A Monk, BJ
Citation: K. Tewari et al., Interstitial brachytherapy in the treatment of advanced and recurrent vulvar cancer, AM J OBST G, 181(1), 1999, pp. 91-98
Young age as a prognostic factor in cervical cancer: Results of a population-based study
Authors: Brewster, WR DiSaia, PJ Monk, BJ Ziogas, A Yamada, SD Anton-Culver, H
Citation: Wr. Brewster et al., Young age as a prognostic factor in cervical cancer: Results of a population-based study, AM J OBST G, 180(6), 1999, pp. 1464-1467
In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers
Authors: Monk, BJ Alberts, DS Burger, RA Fanta, PT Hallum, AV Hatch, KD Salmon, SE
Citation: Bj. Monk et al., In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers, GYNECOL ONC, 71(2), 1998, pp. 308-312
Risultati: 1-17 |